Back to results
US 2026/0160770 A1Published application
Compositions and methods for assessing and treating chemotherapy-induced peripheral neuropathy
AssigneeLankenau Institute for Medical Research
InventorsU. Margaretha Wallon, Nolan L. Metz
Life of this patent
Estimating the term…
Abstract
Methods and compositions for assessing the susceptibility of a subject to chemotherapy induced neuropathy (CIPN) comprising obtaining one or more measurement of the GSH recycling dependent antioxidant activity of the subject's red blood cells are provided.
Claims34
A method of assessing susceptibility to or severity of chemotherapy-induced neuropathy (CIPN) in a subject administered a chemotherapeutic agent, the method comprising:
- (a) obtaining a baseline measurement of glutathione (GSH) recycling activity in one or more biological samples containing red blood cells (RBC) obtained from the subject prior to a first administration of a chemotherapeutic agent;
- (b) obtaining a first measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following a first administration of the chemotherapeutic agent, but prior to a second administration of the chemotherapeutic agent;
- (c) obtaining a second measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following the second administration of the chemotherapeutic agent, but prior to a third administration of the chemotherapeutic agent;
- (d) obtaining a third measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following the third administration of the chemotherapeutic agent, but prior to a fourth administration of the chemotherapeutic agent;
- (e) obtaining an average of the baseline measurement, the first measurement, the second measurement, and the third measurement;
- wherein an average of 1.85 or less is indicative of susceptibility to or severity of CIPN.
3 more elements
A method of assessing susceptibility to or severity of chemotherapy-induced neuropathy (CIPN) in a subject administered a chemotherapeutic agent, the method comprising:
- (a) obtaining a first measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following a first administration of the chemotherapeutic agent, but prior to a second administration of the chemotherapeutic agent;
- (b) obtaining a second measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following the third administration of the chemotherapeutic agent, but prior to a fourth administration of the chemotherapeutic agent;
- (c) obtaining an average of the baseline measurement, the first measurement, and the second measurement,
- wherein an average of 1.8 or less is indicative of susceptibility to or severity of CIPN.
1 more element
A method of assessing susceptibility to or predicting severity of chemotherapy-induced neuropathy (CIPN) in a subject administered a chemotherapeutic agent, the method comprising:
- (a) obtaining a baseline measurement of glutathione (GSH) recycling activity in one or more biological samples containing red blood cells (RBC) obtained from the subject prior to a first administration of a chemotherapeutic agent;
- (b) obtaining
- (i) a measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following a first administration of the chemotherapeutic agent, but prior to a second administration of the chemotherapeutic agent;
- (ii) a measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following a second administration of the chemotherapeutic agent, but prior to a third administration of the chemotherapeutic agent;
- or
- (iii) obtaining a measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following a third administration of the chemotherapeutic agent, but prior to a fourth administration of the chemotherapeutic agent;
- wherein a decrease in GSH recycling activity is predictive of increased susceptibility to or severity of CIPN.
4 more elements
A method of reducing susceptibility to CIPN following treatment with a chemotherapeutic agent, the method comprising
- (a) obtaining a baseline measurement of glutathione (GSH) recycling activity in one or more biological samples containing red blood cells (RBC) obtained from the subject prior to a first administration of a chemotherapeutic agent;
- (b) obtaining a first measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following a first administration of the chemotherapeutic agent, but prior to a second administration of the chemotherapeutic agent;
- (c) obtaining a second measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following the second administration of the chemotherapeutic agent, but prior to a third administration of the chemotherapeutic agent;
- (d) obtaining a third measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following the third administration of the chemotherapeutic agent, but prior to a fourth administration of the chemotherapeutic agent;
- (e) obtaining an average of the baseline measurement, the first measurement, the second measurement, and the third measurement, wherein an average of 1.85 or less is indicative of susceptibility to or severity of CIPN;
- and
- (f) altering the subject's treatment regimen to reduce susceptibility to or severity of chemotherapy-induced neuropathy (CIPN), and/or administering a treatment for CIPN.
4 more elements
A method of reducing susceptibility to CIPN following treatment with a chemotherapeutic agent, the method comprising
- (a) obtaining a first measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following a first administration of the chemotherapeutic agent, but prior to a second administration of the chemotherapeutic agent;
- (b) obtaining a second measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following the third administration of the chemotherapeutic agent, but prior to a fourth administration of the chemotherapeutic agent;
- (c) obtaining an average of the first measurement and the second measurement, wherein an average of 1.8 or less is indicative of susceptibility to or severity of CIPN;
- and
- (d) altering the subject's treatment regimen to reduce susceptibility to or severity of chemotherapy-induced neuropathy (CIPN), and/or administering a treatment for CIPN.
2 more elements
A method of reducing susceptibility to CIPN following treatment with a chemotherapeutic agent, the method comprising
- (a) obtaining a baseline measurement of glutathione (GSH) recycling activity in one or more biological samples containing red blood cells (RBC) obtained from the subject prior to a first administration of a chemotherapeutic agent;
- (b) obtaining
- (i) a measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following a first administration of the chemotherapeutic agent, but prior to a second administration of the chemotherapeutic agent;
- (ii) a measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following a second administration of the chemotherapeutic agent, but prior to a third administration of the chemotherapeutic agent;
- or
- (iii) obtaining a measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following a third administration of the chemotherapeutic agent, but prior to a fourth administration of the chemotherapeutic agent;
- wherein a decrease in GSH recycling activity is predictive of increased severity of or susceptibility to CIPN;
- and
- (c) altering the subject's treatment regimen to reduce susceptibility to or severity of chemotherapy-induced neuropathy (CIPN), and/or administering a treatment for CIPN.
6 more elements
A method for assessing the ability of a treatment to alter susceptibility to or severity of chemotherapy-induced neuropathy (CIPN) in a subject, the method comprising:
- (a) obtaining a baseline measurement of glutathione (GSH) recycling activity in one or more biological samples containing red blood cells (RBC) obtained from the subject prior to a first administration of a chemotherapeutic agent;
- (b) obtaining a first measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following a first administration of the chemotherapeutic agent, but prior to a second administration of the chemotherapeutic agent;
- (c) obtaining a second measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following the second administration of the chemotherapeutic agent, but prior to a third administration of the chemotherapeutic agent;
- (d) obtaining a third measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following the third administration of the chemotherapeutic agent, but prior to a fourth administration of the chemotherapeutic agent;
- (e) obtaining an average of the baseline measurement, the first measurement, the second measurement, and the third measurement, wherein an average of 1.85 or less is indicative of susceptibility to or severity of CIPN;
- and
- (f) administering the treatment for CIPN to the subject.
4 more elements
A method for assessing the ability of a treatment to alter susceptibility to or severity of chemotherapy-induced neuropathy (CIPN) in a subject, the method comprising:
- (a) obtaining a first measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following a first administration of the chemotherapeutic agent, but prior to a second administration of the chemotherapeutic agent;
- (b) obtaining a second measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following the third administration of the chemotherapeutic agent, but prior to a fourth administration of the chemotherapeutic agent;
- (c) obtaining an average of the baseline measurement, the first measurement, and the second administration, wherein an average of 1.8 or less is indicative of susceptibility to or severity of CIPN;
- and
- (d) administering the treatment for CIPN to the subject.
2 more elements
A method for assessing the ability of a treatment to alter susceptibility to or severity of chemotherapy-induced neuropathy (CIPN) in a subject, the method comprising:
- (a) obtaining a baseline measurement of glutathione (GSH) recycling activity in one or more biological samples containing red blood cells (RBC) obtained from the subject prior to a first administration of a chemotherapeutic agent;
- (b) obtaining
- (i) a measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following a first administration of the chemotherapeutic agent, but prior to a second administration of the chemotherapeutic agent;
- (ii) a measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following a second administration of the chemotherapeutic agent, but prior to a third administration of the chemotherapeutic agent;
- or
- (iii) obtaining a measurement of GSH recycling activity in one or more biological samples containing RBC obtained from the subject following a third administration of the chemotherapeutic agent, but prior to a fourth administration of the chemotherapeutic agent;
- wherein a decrease in GSH recycling activity is predictive of increased susceptibility to or severity of CIPN;
- and
- (c) administering the treatment for CIPN to the subject.
6 more elements
Dependencies are inferred from the claim text.